EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment

Tian-Yuan Xu, Rong-Ji Mu, Hui-Lai Zhang, Bing Xu, Rong Li, Nan Wang, Rui Sun, Rui-Chi Li, Di Fu, Xian-Huo Wang iD, Zhi-Feng Li, Yan Zhao und 6 weitere

HemaSphere · 2025-05 · 9 (5)

DOI: 10.1002/hem3.70141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 07.05.2025. Verfasst von Tian-Yuan Xu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hos…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular lymphoma (FL) patients with low tumor burden at diagnosis frequently undergo the watch‐and‐wait (W&W) strategy. The study aimed to facilitate risk assessment in predicting the time to lymphoma treatment (TLT) for W&W patients through an integrated analysis of clinical factors and genetic mutations. A retrospective study was conducted on 214 FL patients managed with W&W between 2016 and 2023. Among them, 184 patients underwent targeted sequencing. The median follow‐up was 30.4 months (IQR 21.4–41.9, range 6.4–95.8). A clinico‐genetic model m3‐PRIMA‐PI was developed using the multivariate Cox proportional hazards method, incorporating two clinical parameters (bone marrow involvement and elevated β2‐MG) and three gene mutations ( KMT2D , EP300 , and TP53 ). Patients were categorized into low (69.0%), intermediate (21.7%), and high (9.2%) risk groups. Probabilities of treatment initiation at one year were 11.0% (95% CI, 5.2%–16.5%), 26.0% (95% CI, 10.7%–38.7%), and 54.3% (95% CI, 22.3%–73.1%); and at 2 years were 29.4% (95% CI, 20.2%–37.5%), 49.8% (95% CI, 31.1%–63.4%), and 93.5% (95% CI, 56.7%–99.0%), respectively. The predictive performance for TLT was superior with m3‐PRIMA‐PI, achieving a C‐index of 0.66 (95% CI, 0.63–0.69), compared to established indexes like FLIPI (C‐index 0.59, 95% CI, 0.56–0.62) and FLIPI2 (C‐index 0.59, 95% CI, 0.55–0.61). The above results were further validated in an independent external cohort. The m3‐PRIMA‐PI may provide a promising tool for risk stratification in W&W FL patients.

Autor:innen und Institutionen

  • Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine S…
  • Clinical Research Institute Shanghai Jiao Tong University School of Medicine Shanghai China.
  • Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianj…
  • Department of Hematology The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University Xiamen China.
  • Department of Hematology, Navy Medical Center of PLA Naval Medical University Changning District Shanghai China.
  • Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology Shanghai China.

ORCID-Profile: Xian-Huo Wang, Wei-Li Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, T. Y., Mu, R. J., Zhang, H. L., Xu, B., Li, R., Wang, N., Sun, R., Li, R. C., Fu, D., Wang, X. H., Li, Z. F., Zhao, Y., Xu, P. P., Cheng, S., Wang, L., Tang, W., Zheng, Z., & Zhao, W. L. (2025). Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment. HemaSphere, 9(5). https://doi.org/10.1002/hem3.70141

Vancouver

Xu TY, Mu RJ, Zhang HL, Xu B, Li R, Wang N, et al. Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment. HemaSphere. 2025;9(5). doi:10.1002/hem3.70141

BibTeX
@article{Xu2025,
  author = {Xu, Tian-Yuan and Mu, Rong-Ji and Zhang, Hui-Lai and Xu, Bing and Li, Rong and Wang, Nan and Sun, Rui and Li, Rui-Chi and Fu, Di and Wang, Xian-Huo and Li, Zhi-Feng and Zhao, Yan and Xu, Peng-Peng and Cheng, Shu and Wang, Li and Tang, Wei and Zheng, Zhong and Zhao, Wei-Li},
  title = {Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment},
  journal = {HemaSphere},
  year = {2025},
  volume = {9},
  number = {5},
  doi = {10.1002/hem3.70141}
}
Kostenlos starten →